drugset
drugset / Trial / NCT02128113

RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD

NCT02128113 ↗

Phase 2 Completed 307 enrolled Biogen AbbVie · collab
RandomizedParallel-groupDouble-blindPrevention

Summary

This study assesses the efficacy and safety of two concentrations of omaveloxolone (RTA 408) ophthalmic suspension for the prevention of corneal endothelial cell loss following cataract surgery.

Timeline

Start
2014-05-31
Primary completion
2015-02-28
Completion
2015-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Omaveloxolone Small molecule 0.5 % Other
Subject Omaveloxolone Small molecule 1 % Other

Indications

cataract corneal disorder